Enanta Pharmaceuticals, Inc. (ENTA) Stock Grade

About Enanta Pharmaceuticals, Inc.'s fundamentals

Enanta Pharmaceuticals is a biotechnology company with a market capitalization of $255.4 million that is currently unprofitable, having reported a net loss in its latest annual statement with a net margin of -125.4%. The company experienced a revenue decline of 3.4% year-over-year, indicating contracting sales in its most recent period. With no dividend payment and standard profitability metrics unavailable, the company appears to be in a development or transition phase typical of smaller biotech firms that rely on pipeline progress rather than current earnings.